-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This article is original for Translational Medicine.
Please indicate the source when reprinting.
Author: Jasmine Introduction: Leukemia is a malignant clonal disease of hematopoietic stem cells
.
Although leukemia can be treated with a bone marrow transplant, the cancer cells cannot be completely eliminated
.
Once the disease recurs, not only the treatment difficulty factor will increase, but also the pain of the patient's treatment
.
Recently, Dr.
Carl June, the father of CAR-T, and his team, after more than ten years of clinical research, have proved that CAR-T therapy can completely cure this kind of cancer, and CAR-T cells can stay in the body for many years, inhibiting disease recurrence
.
In 2010, doctors performed experimental gene therapy on Doug Olson's leukemia, turning some of his blood cells into "cancer killers
.
"
For more than a decade since then, his cancer has shown no signs of returning
.
In addition to Olson, the treatment also cured another patient, Ludwig, the Penn medical team said, the first clinical study of the treatment for such a long period of time
.
Olson, 75, who lives in Pleasanton, Calif.
, said: "I'm in great shape and full of energy
.
I was running a half-marathon until 2018.
I
'm
totally healed.
, You must know that doctors will not easily say the word 'cure' to leukemia patients
.
"Recently, Olson's doctor published a study in "Nature" titled "Decade-long leukaemia remissions with persistence of CD4 CAR T cells+", describing these two cases
.
The research paper wrote that the two The case shows that CAR-T cells can attack cancer cells immediately, then stay in the body for years and evolve to control the disease
.
https://doi.
org/10.
1038/s41586-021-04390-6 Based on research As a result, "We can now conclude that CAR-T cells can indeed cure leukemia patients
.
CAR
-
T therapy requires harvesting a patient's T cells, as well as white blood cells that play a key role in the immune system, and then engineering them in the lab so that they can recognize and attack cancer cells, and finally The modified cells are injected back into the patient intravenously
.
Olson received CAR-T therapy after years of battling cancer
.
Doctors diagnosed him with chronic lymphocytic leukemia in 1996, thinking he could only A few months to live
.
That's when his doctor, David Porter, said he might need a bone marrow transplant
.
Porter also advised him to join a clinical study of cell therapy
.
Olson was the CEO of a laboratory products company in New Hampshire at the time .
Officer, he was interested in the science and didn't want a bone marrow transplant, so he took Porter's advice
.
After several weeks of treatment, he developed nausea and spent three days in hospital
.
"Then the doctor said to me, 'We don't see any cancer cells in your body,'" Olson recalls
.
Another patient, Bill Ludwig, was similarly treated
.
The modified cells evolved over time, with many turning into "helper" cells that worked together to fight cancer cells, the researchers said
.
Helper cells eventually dominated in both patients, and the leukemia was effectively treated
.
J.
Joseph Melenhorst, an author on the research paper, said they were able to isolate and analyze the cells using new techniques, which allowed them to better see how CAR-T cells persisted in patients
.
Tens of thousands of patients are currently being treated with CAR-T cell therapy, which has been approved by health authorities around the world, including the FDA, for certain blood cancers, June said
.
In 2017, the agency first approved a CAR-T therapy developed by the University of Pennsylvania and drugmaker Novartis to treat childhood leukemia
.
CAR-T cells to be infused into patients (source: cancer.
gov) Scientists hope that CAR-T therapy will be more widely used to treat other cancers
.
A CAR-T cell therapy for multiple myeloma was approved last year
.
Multiple myeloma is the most common malignant tumor in the adult bone marrow
.
Leukemia, lymphoma and myeloma accounted for less than 10 percent of the 1.
9 million new cancer cases in the U.
S.
last year, according to the Leukemia & Lymphoma Society.
.
"But the biggest challenge is getting CAR-T cell therapy to work in solid tumors, such as lung, colon and other parts of the body,
"
June said
.
Even treating blood cancers presents many challenges
.
These treatments are very expensive, costing hundreds of thousands of dollars just for the drugs
.
In addition, there is a risk of serious side effects, including immune overreaction, also known as "cytokine release syndrome," and neurological-related problems, such as brain swelling
.
Two patients at the University of Pennsylvania have had excellent outcomes after treatment
.
Ludwig and his wife drove the motorhome around the country until they died of complications from COVID-19 early last year
.
Olson is unfortunate and lucky
.
Although he was terminally ill, he was cured
.
He has lived gratefully since his recovery, saying, "What is changing is the dimension of hope, what is found is the hope of living
.
" Reference: https://medicalxpress.
com/news/2022-02-doctors- long-lasting-cell-treatment-leukemia.
htmlNote: This article is intended to introduce the progress of medical research and cannot be used as a reference for treatment plans
.
For health guidance, please go to a regular hospital for treatment
.
Recommendation·Event The first Yangtze River Delta single-cell omics technology application forum "Drug Precision" series of live broadcasts: the second phase of MRD detection and Car-T cell therapy development popular articles Organoid research [year-end inventory] must-see in the field of organoids in 2021 Essential Research Content Medical Research [Cell Sub-Journal] Optimization Technology! Restore human cells to stem cell state! Cancer Research [Science Sub-Journal] Will "lactic acid" help cancer cells? Studies have found that specific enzymes can fight it! Genetic Testing【Science Sub-Journal】A previously unknown gene mutation, BAG5, can cause incurable heart disease cancer research 【Science Sub-Journal】“Pseudogene” carcinogenic? Research identifies a new pathway leading to liver cancer -- pseudogene demethylation, which could help develop new treatments! New research shows how to test the effectiveness of anti-cancer drugs
Please indicate the source when reprinting.
Author: Jasmine Introduction: Leukemia is a malignant clonal disease of hematopoietic stem cells
.
Although leukemia can be treated with a bone marrow transplant, the cancer cells cannot be completely eliminated
.
Once the disease recurs, not only the treatment difficulty factor will increase, but also the pain of the patient's treatment
.
Recently, Dr.
Carl June, the father of CAR-T, and his team, after more than ten years of clinical research, have proved that CAR-T therapy can completely cure this kind of cancer, and CAR-T cells can stay in the body for many years, inhibiting disease recurrence
.
In 2010, doctors performed experimental gene therapy on Doug Olson's leukemia, turning some of his blood cells into "cancer killers
.
"
For more than a decade since then, his cancer has shown no signs of returning
.
In addition to Olson, the treatment also cured another patient, Ludwig, the Penn medical team said, the first clinical study of the treatment for such a long period of time
.
Olson, 75, who lives in Pleasanton, Calif.
, said: "I'm in great shape and full of energy
.
I was running a half-marathon until 2018.
I
'm
totally healed.
, You must know that doctors will not easily say the word 'cure' to leukemia patients
.
"Recently, Olson's doctor published a study in "Nature" titled "Decade-long leukaemia remissions with persistence of CD4 CAR T cells+", describing these two cases
.
The research paper wrote that the two The case shows that CAR-T cells can attack cancer cells immediately, then stay in the body for years and evolve to control the disease
.
https://doi.
org/10.
1038/s41586-021-04390-6 Based on research As a result, "We can now conclude that CAR-T cells can indeed cure leukemia patients
.
CAR
-
T therapy requires harvesting a patient's T cells, as well as white blood cells that play a key role in the immune system, and then engineering them in the lab so that they can recognize and attack cancer cells, and finally The modified cells are injected back into the patient intravenously
.
Olson received CAR-T therapy after years of battling cancer
.
Doctors diagnosed him with chronic lymphocytic leukemia in 1996, thinking he could only A few months to live
.
That's when his doctor, David Porter, said he might need a bone marrow transplant
.
Porter also advised him to join a clinical study of cell therapy
.
Olson was the CEO of a laboratory products company in New Hampshire at the time .
Officer, he was interested in the science and didn't want a bone marrow transplant, so he took Porter's advice
.
After several weeks of treatment, he developed nausea and spent three days in hospital
.
"Then the doctor said to me, 'We don't see any cancer cells in your body,'" Olson recalls
.
Another patient, Bill Ludwig, was similarly treated
.
The modified cells evolved over time, with many turning into "helper" cells that worked together to fight cancer cells, the researchers said
.
Helper cells eventually dominated in both patients, and the leukemia was effectively treated
.
J.
Joseph Melenhorst, an author on the research paper, said they were able to isolate and analyze the cells using new techniques, which allowed them to better see how CAR-T cells persisted in patients
.
Tens of thousands of patients are currently being treated with CAR-T cell therapy, which has been approved by health authorities around the world, including the FDA, for certain blood cancers, June said
.
In 2017, the agency first approved a CAR-T therapy developed by the University of Pennsylvania and drugmaker Novartis to treat childhood leukemia
.
CAR-T cells to be infused into patients (source: cancer.
gov) Scientists hope that CAR-T therapy will be more widely used to treat other cancers
.
A CAR-T cell therapy for multiple myeloma was approved last year
.
Multiple myeloma is the most common malignant tumor in the adult bone marrow
.
Leukemia, lymphoma and myeloma accounted for less than 10 percent of the 1.
9 million new cancer cases in the U.
S.
last year, according to the Leukemia & Lymphoma Society.
.
"But the biggest challenge is getting CAR-T cell therapy to work in solid tumors, such as lung, colon and other parts of the body,
"
June said
.
Even treating blood cancers presents many challenges
.
These treatments are very expensive, costing hundreds of thousands of dollars just for the drugs
.
In addition, there is a risk of serious side effects, including immune overreaction, also known as "cytokine release syndrome," and neurological-related problems, such as brain swelling
.
Two patients at the University of Pennsylvania have had excellent outcomes after treatment
.
Ludwig and his wife drove the motorhome around the country until they died of complications from COVID-19 early last year
.
Olson is unfortunate and lucky
.
Although he was terminally ill, he was cured
.
He has lived gratefully since his recovery, saying, "What is changing is the dimension of hope, what is found is the hope of living
.
" Reference: https://medicalxpress.
com/news/2022-02-doctors- long-lasting-cell-treatment-leukemia.
htmlNote: This article is intended to introduce the progress of medical research and cannot be used as a reference for treatment plans
.
For health guidance, please go to a regular hospital for treatment
.
Recommendation·Event The first Yangtze River Delta single-cell omics technology application forum "Drug Precision" series of live broadcasts: the second phase of MRD detection and Car-T cell therapy development popular articles Organoid research [year-end inventory] must-see in the field of organoids in 2021 Essential Research Content Medical Research [Cell Sub-Journal] Optimization Technology! Restore human cells to stem cell state! Cancer Research [Science Sub-Journal] Will "lactic acid" help cancer cells? Studies have found that specific enzymes can fight it! Genetic Testing【Science Sub-Journal】A previously unknown gene mutation, BAG5, can cause incurable heart disease cancer research 【Science Sub-Journal】“Pseudogene” carcinogenic? Research identifies a new pathway leading to liver cancer -- pseudogene demethylation, which could help develop new treatments! New research shows how to test the effectiveness of anti-cancer drugs
